Ascentage Pharma (AAPG) announced that it has received clearance by the U.S. Food and Drug Administration, FDA, and the European Medicines Agency, EMA, to conduct GLORA-4 study, a global registrational Phase III study of lisaftoclax, APG-2575, a proprietary Bcl-2 inhibitor, in combination with azacitidine, for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAPG:
- Ascentage Pharma to Announce 2025 Interim Results and Corporate Update
- Ascentage Pharma to Engage in Evercore China Biotech Summit
- Ascentage Pharma Completes Offshore Placement to Boost Global Operations
- Ascentage Pharma announces China NMPA approval of lisaftoclax
- Ascentage Pharma Strengthens Leadership with Key Appointments